Performance TechnologiesPTIX
PTIX
About: Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Employees: 3
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.57% more ownership
Funds ownership: 2.1% [Q4 2024] → 4.67% (+2.57%) [Q1 2025]
0% more funds holding
Funds holding: 9 [Q4 2024] → 9 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
12% less capital invested
Capital invested by funds: $75K [Q4 2024] → $65.9K (-$9.11K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for PTIX.
Financial journalist opinion
Based on 4 articles about PTIX published over the past 30 days
Neutral
Accesswire
3 weeks ago
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
Neutral
Benzinga
3 weeks ago
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.
Neutral
Business Wire
3 weeks ago
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to Protagenic shareholders. Upon completion of the proposed transaction, Protagenic shareholders are expected to own approximately 35% of the combined company. Halper Sadeh encourages Protagenic shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Hal.
Neutral
Accesswire
3 weeks ago
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders
NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset.
Neutral
Accesswire
1 month ago
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, today announced that the Company's Board of Directors has approved a 1-for-14 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on May 5, 2025.
Neutral
Accesswire
7 months ago
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders).
Neutral
Accesswire
7 months ago
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants will be $0.64 ($0.89 in the case of insiders).
Neutral
Accesswire
1 year ago
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms.
Neutral
Accesswire
1 year ago
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a talk on PT00114, the company's promising new drug candidate, at the Peptide Based Therapeutic Summit in Boston. Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment," Dr. Slee's talk will focus on the groundbreaking structure of PT00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditions.
Neutral
Seeking Alpha
1 year ago
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Charts implemented using Lightweight Charts™